CoChat
Sign Up
Cited by 221Antibiotic Resistance in BacteriaPharmaceutical and Antibiotic Environmental ImpactsInfections and bacterial resistance

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Mobile Carbapenemase Genes in Pseudomonas aeruginosa

Open access
Yoon, Eun-Jeong, Jeong, Seok Hoon·2021·Frontiers in Microbiology
DOI 10.3389/fmicb.2021.614058PMC PMC7930500
Open this paper in CoChat — free accountOpen PDF

Abstract

Carbapenem-resistant Pseudomonas aeruginosa is one of the major concerns in clinical settings impelling a great challenge to antimicrobial therapy for patients with infections caused by the pathogen. While membrane permeability, together with derepression of the intrinsic beta-lactamase gene, is the global prevailing mechanism of carbapenem resistance in P. aeruginosa, the acquired genes for carbapenemases need special attention because horizontal gene transfer through mobile genetic elements, such as integrons, transposons, plasmids, and integrative and conjugative elements, could accelerate the dissemination of the carbapenem-resistant P. aeruginosa. This review aimed to illustrate epidemiologically the carbapenem resistance in P. aeruginosa, including the resistance rates worldwide and the carbapenemase-encoding genes along with the mobile genetic elements responsible for the horizontal dissemination of the drug resistance determinants. Moreover, the modular mobile elements including the carbapenemase-encoding gene, also known as the P. aeruginosa resistance islands, are scrutinized mostly for their structures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2021.614058

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Carbapenem drugs. The backbone of carbapenems is in a box. The C-1 position replaced from the sulfur atom in the penicillin backbone is indicated with a red dot. The important R1 and R3 positions are indicated with red letters. Ertapenem with a bulky R3 residue, which does not have enough affinity to be active against Pseudomonas aeruginosa, is presented with the other three carbapenems having antipseudomonal activity.
FIGURE 1 Carbapenem drugs. The backbone of carbapenems is in a box. The C-1 position replaced from the sulfur atom in the penicillin backbone is indicated with a red dot. The important R1 and R3 positions are indicated with red letters. Ertapenem with a bulky R3 residue, which does not have enough affinity to be active against Pseudomonas aeruginosa, is presented with the other three carbapenems having antipseudomonal activity.CC BY · PubMed Central
FIGURE 2 A stereoview of PBP3 of Pseudomonas aeruginosa complexed with meropenem (PDB ID, 3PBR) and the interaction of the meropenem in the ligand pocket of PBP3 (Han et al., 2010). The structure of PBP3 is colored by secondary structure, and the meropenem is in a ball-and-stick presentation. The molecular surface of PBP3 in the binding pocket is presented with the interacting amino acid residue complex with meropenem in a ball-and-stick presentation.
FIGURE 2 A stereoview of PBP3 of Pseudomonas aeruginosa complexed with meropenem (PDB ID, 3PBR) and the interaction of the meropenem in the ligand pocket of PBP3 (Han et al., 2010). The structure of PBP3 is colored by secondary structure, and the meropenem is in a ball-and-stick presentation. The molecular surface of PBP3 in the binding pocket is presented with the interacting amino acid residue complex with meropenem in a ball-and-stick presentation.CC BY · PubMed Central
FIGURE 3 Rates of imipenem resistance in Pseudomonas aeruginosa worldwide in 2018. All the data were extracted from the Antimicrobial Testing Leadership and Surveillance run by Pfizer (last updated on October 30, 2019) (Pfizer, 2020), except for the data from South Korea (unpublished data). The actual resistance rates are indicated per continent as follows: Africa [three participating countries: Morocco (N = 79, 22.8%), Nigeria (N = 38, 13.2%), South Africa (N = 98, 21.4%)]; Asia [10 participating countries: China (N = 386, 33.2%), Hong Kong (N = 25, 24%), India (N = 125, 29.6%), Japan (N = 75, 8%), Malaysia (N = 55, 21.8%), Philippines (N = 74, 18.9%), Singapore (N = 25, 16%), South Korea (N = 127, 18.1%), Taiwan (N = 99, 9.1%), and Thailand (N = 75, 16%)]; Europe [24 participating countries: Belgium (N = 150, 21.3%), Croatia (N = 78, 35.9%), Czech Republic (N = 102, 29.4%), Denmark (N = 25, 8%), Finland (N = 19, 0%), France (N = 248, 20.2%), Germany (N = 248, 27.4%), Greece (N = 75, 30.7%), Hungary (N = 100, 42%), Ireland (N = 64, 18.8%), Italy (N = 242, 28.5%), Latvia (N = 24, 33.3%), Lithuania (N = 50, 22%), Poland (N = 101, 39.6%), Portugal (N = 99, 32.3%), Romania (N = 99, 45.5%), Russia (N = 194, 48.5%), Netherlands (N = 40, 17.5%), Spain (N = 273, 19.4%), Sweden (N = 25, 8%), Switzerland (N = 50, 10%), Turkey (N = 60, 43.3%), Ukraine (N = 53, 54.7%), and United Kingdom (N = 158, 19.6%)]; Mid and South America [10 participating countries: Brazil (N = 116, 16.4%), Chile (N = 75, 49.3%), Colombia (N = 124, 30.7%), Costa Rica (N = 22, 13.6%), Dominican Republic (N = 24, 12.5%), Guatemala (N = 55, 16.4%), Mexico (N = 146, 42.5%), Panama (N = 32, 37.5%), and Venezuela (N = 64, 45.3%)]; North America [two participating countries: Canada (N = 197, 27.4%) and the United States (N = 588, 21.4%),]; Middle East [four participating countries: Israel (N = 100, 12%), Jordan (N = 24, 29.2%), Kuwait (N = 76, 44.7%), and Saudi Arabia (N = 26, 38.5%)]; and Oceania [a single participating country: Australia (N = 99, 7.1%)].
FIGURE 3 Rates of imipenem resistance in Pseudomonas aeruginosa worldwide in 2018. All the data were extracted from the Antimicrobial Testing Leadership and Surveillance run by Pfizer (last updated on October 30, 2019) (Pfizer, 2020), except for the data from South Korea (unpublished data). The actual resistance rates are indicated per continent as follows: Africa [three participating countries: Morocco (N = 79, 22.8%), Nigeria (N = 38, 13.2%), South Africa (N = 98, 21.4%)]; Asia [10 participating countries: China (N = 386, 33.2%), Hong Kong (N = 25, 24%), India (N = 125, 29.6%), Japan (N = 75, 8%), Malaysia (N = 55, 21.8%), Philippines (N = 74, 18.9%), Singapore (N = 25, 16%), South Korea (N = 127, 18.1%), Taiwan (N = 99, 9.1%), and Thailand (N = 75, 16%)]; Europe [24 participating countries: Belgium (N = 150, 21.3%), Croatia (N = 78, 35.9%), Czech Republic (N = 102, 29.4%), Denmark (N = 25, 8%), Finland (N = 19, 0%), France (N = 248, 20.2%), Germany (N = 248, 27.4%), Greece (N = 75, 30.7%), Hungary (N = 100, 42%), Ireland (N = 64, 18.8%), Italy (N = 242, 28.5%), Latvia (N = 24, 33.3%), Lithuania (N = 50, 22%), Poland (N = 101, 39.6%), Portugal (N = 99, 32.3%), Romania (N = 99, 45.5%), Russia (N = 194, 48.5%), Netherlands (N = 40, 17.5%), Spain (N = 273, 19.4%), Sweden (N = 25, 8%), Switzerland (N = 50, 10%), Turkey (N = 60, 43.3%), Ukraine (N = 53, 54.7%), and United Kingdom (N = 158, 19.6%)]; Mid and South America [10 participating countries: Brazil (N = 116, 16.4%), Chile (N = 75, 49.3%), Colombia (N = 124, 30.7%), Costa Rica (N = 22, 13.6%), Dominican Republic (N = 24, 12.5%), Guatemala (N = 55, 16.4%), Mexico (N = 146, 42.5%), Panama (N = 32, 37.5%), and Venezuela (N = 64, 45.3%)]; North America [two participating countries: Canada (N = 197, 27.4%) and the United States (N = 588, 21.4%),]; Middle East [four participating countries: Israel (N = 100, 12%), Jordan (N = 24, 29.2%), Kuwait (N = 76, 44.7%), and Saudi Arabia (N = 26, 38.5%)]; and Oceania [a single participating country: Australia (N = 99, 7.1%)].CC BY · PubMed Central
FIGURE 4 Worldwide identification of the carbapenemase-producing Pseudomonas aeruginosa. Reports of class A [Klebsiella pneumoniae carbapenemase (KPC) and Guiana extended-spectrum beta-lactamase (GES) with amino acid alteration at aa 170], class B [Verona integron-encoded MBL (VIM), imipenemase (IMP), New Delhi MBL (NDM), and others], and class D (OXA) carbapenemases are indicated in a geographic map. The references used for the map drawing are indicated in the main text.
FIGURE 4 Worldwide identification of the carbapenemase-producing Pseudomonas aeruginosa. Reports of class A [Klebsiella pneumoniae carbapenemase (KPC) and Guiana extended-spectrum beta-lactamase (GES) with amino acid alteration at aa 170], class B [Verona integron-encoded MBL (VIM), imipenemase (IMP), New Delhi MBL (NDM), and others], and class D (OXA) carbapenemases are indicated in a geographic map. The references used for the map drawing are indicated in the main text.CC BY · PubMed Central
FIGURE 5 Epidemic carbapenemase-producing high-risk Pseudomonas aeruginosa clones identified worldwide. Regional dissemination of specific P. aeruginosa clones identified through multilocus sequence typing (MLST) is indicated in color on a geographic map, and the carbapenemases produced are indicated at the region. The number of countries with reports of the P. aeruginosa clone are indicated in the figure legends. References are indicated in the main text.
FIGURE 5 Epidemic carbapenemase-producing high-risk Pseudomonas aeruginosa clones identified worldwide. Regional dissemination of specific P. aeruginosa clones identified through multilocus sequence typing (MLST) is indicated in color on a geographic map, and the carbapenemases produced are indicated at the region. The number of countries with reports of the P. aeruginosa clone are indicated in the figure legends. References are indicated in the main text.CC BY · PubMed Central
FIGURE 6 Transposable units identified in Pseudomonas aeruginosa carrying the carbapenemase-encoding genes. The red arrow indicates the genes for antimicrobial resistance, and those with yellow letters inside indicate the genes for carbapenemase. Yellow arrows depict insertion sequences, and those in orange indicate transposase/resolvase.
FIGURE 6 Transposable units identified in Pseudomonas aeruginosa carrying the carbapenemase-encoding genes. The red arrow indicates the genes for antimicrobial resistance, and those with yellow letters inside indicate the genes for carbapenemase. Yellow arrows depict insertion sequences, and those in orange indicate transposase/resolvase.CC BY · PubMed Central
FIGURE 7 Mechanisms of replicative transposition of the transposons. (A) Insertion sequence with a common region (ISCR)-mediated rolling circle replicative transposition is involved in rolling circle replication. ISCR elements lack terminal inverted repeats, and a single copy of the element is able to transpose adjacent DNA sequences (Toleman et al., 2006). (B) A Tn3-mediated copy-and-paste replicative transposition requires both a transposase and a resolvase. The transposon is replicated, joining the donor and the recipient in a cointegrate, which is resolved to give the donor and the recipient of the transposon (Grindley, 1983).
FIGURE 7 Mechanisms of replicative transposition of the transposons. (A) Insertion sequence with a common region (ISCR)-mediated rolling circle replicative transposition is involved in rolling circle replication. ISCR elements lack terminal inverted repeats, and a single copy of the element is able to transpose adjacent DNA sequences (Toleman et al., 2006). (B) A Tn3-mediated copy-and-paste replicative transposition requires both a transposase and a resolvase. The transposon is replicated, joining the donor and the recipient in a cointegrate, which is resolved to give the donor and the recipient of the transposon (Grindley, 1983).CC BY · PubMed Central
FIGURE 8 Organization of the integron and the process of capturing and exchanging the gene cassettes. The open arrow indicates the open reading frame and is colored based on its function: the antimicrobial resistance gene is in red or in magenta, the attC gene is in green, and the intI1 gene is in orange. The open box indicates the attI locus. The integron is organized as a functional platform including the intI1 gene and the attI locus and a cassette array assembled through the acquisition of gene cassettes structured with an open reading frame and an attC locus. Expression of the gene cassettes is dependent on the common promoter, Pc, and the level of expression depends on the distance from the Pc. The IntI1 integrase binds to the attC locus of the excised gene cassette to help circularize the cassette (Collis et al., 1993; Hall and Collis, 1995).
FIGURE 8 Organization of the integron and the process of capturing and exchanging the gene cassettes. The open arrow indicates the open reading frame and is colored based on its function: the antimicrobial resistance gene is in red or in magenta, the attC gene is in green, and the intI1 gene is in orange. The open box indicates the attI locus. The integron is organized as a functional platform including the intI1 gene and the attI locus and a cassette array assembled through the acquisition of gene cassettes structured with an open reading frame and an attC locus. Expression of the gene cassettes is dependent on the common promoter, Pc, and the level of expression depends on the distance from the Pc. The IntI1 integrase binds to the attC locus of the excised gene cassette to help circularize the cassette (Collis et al., 1993; Hall and Collis, 1995).CC BY · PubMed Central
FIGURE 9 Transposons giving mobility to integrons. Transposons are indicated in scale with the component. The accession number of each sequence is indicated in brackets. Arrows indicate open reading frames with filled colors that differ by function: yellow, transposition; orange, class 1 integrase; red, antimicrobial resistance; green, heavy metal resistance (Radstrom et al., 1994; Minakhina et al., 1999; Shi et al., 2018).
FIGURE 9 Transposons giving mobility to integrons. Transposons are indicated in scale with the component. The accession number of each sequence is indicated in brackets. Arrows indicate open reading frames with filled colors that differ by function: yellow, transposition; orange, class 1 integrase; red, antimicrobial resistance; green, heavy metal resistance (Radstrom et al., 1994; Minakhina et al., 1999; Shi et al., 2018).CC BY · PubMed Central
FIGURE 10 Schematic presentation of the structure of genomic islands belonging to the three groups. The schematic structure is presented for the three groups of genomic islands: (A) Group 1 resistance islands equipping the tyrosine-based integrase gene at the 5’ terminal and the conjugative transfer machinery gene cluster at the 3’ terminus, (B) Group 2 resistance islands carrying a transposition module of a whole or a partial TniABQR component, (C) and the others. The genes are indicated with open arrows and colored based on function: genes for integration and recombination of the genomic island are in yellow, genes for antimicrobial resistance (AMR) are in red, genes for heavy metal resistance (HMR) are in green, the intI1 gene is in orange, conjugative transfer module mostly composed of the type 4 pili assembly genes is in black, and the core gene is in gray. The open box indicates inverted repeats (IRs) left and right, named the attL and attR loci for integration conjugative elements.
FIGURE 10 Schematic presentation of the structure of genomic islands belonging to the three groups. The schematic structure is presented for the three groups of genomic islands: (A) Group 1 resistance islands equipping the tyrosine-based integrase gene at the 5’ terminal and the conjugative transfer machinery gene cluster at the 3’ terminus, (B) Group 2 resistance islands carrying a transposition module of a whole or a partial TniABQR component, (C) and the others. The genes are indicated with open arrows and colored based on function: genes for integration and recombination of the genomic island are in yellow, genes for antimicrobial resistance (AMR) are in red, genes for heavy metal resistance (HMR) are in green, the intI1 gene is in orange, conjugative transfer module mostly composed of the type 4 pili assembly genes is in black, and the core gene is in gray. The open box indicates inverted repeats (IRs) left and right, named the attL and attR loci for integration conjugative elements.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 211

  1. Abril, 2019, Genome plasticity favours double chromosomal Tn4401b-blaKPC-2 transposon insertion in the Pseudomonas aeruginosa ST235 clone., BMC Microbiol., 19, 10.1186/s12866-019-1418-6 · DOI
  2. Adam, 2018, Prevalence of metallo-beta-lactamase acquired genes among carbapenems susceptible and resistant Gram-negative clinical isolates using multiplex PCR, Khartoum hospitals, Khartoum Sudan., BMC Infect. Dis., 18, 10.1186/s12879-018-3581-z · DOI
  3. Akpaka, 2009, Emergence of KPC-producing Pseudomonas aeruginosa in Trinidad and Tobago., J. Clin. Microbiol., 47, 2670, 10.1128/jcm.00362-09 · DOI
  4. Al-Agamy, 2009, High prevalence of metallo-beta-lactamase-producing Pseudomonas aeruginosa from Saudi Arabia., J. Chemother., 21, 461, 10.1179/joc.2009.21.4.461 · DOI
  5. Angus, 1982, Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant., Antimicrob. Agents Chemother., 21, 299, 10.1128/aac.21.2.299 · DOI
  6. Arakawa, 1995, A novel integron-like element carrying the metallo-beta-lactamase gene blaIMP., Antimicrob. Agents Chemother., 39, 1612, 10.1128/aac.39.7.1612 · DOI
  7. Araujo, 2018, Insights into a novel Tn4401 deletion (Tn4401i) in a multidrug-resistant Klebsiella pneumoniae clinical strain belonging to the high-risk clonal group 258 producing KPC-2., Int. J. Antimicrob. Agents, 52, 525, 10.1016/j.ijantimicag.2018.08.011 · DOI
  8. Azim, 2010, Epidemiology of bacterial colonization at intensive care unit admission with emphasis on extended-spectrum beta-lactamase- and metallo-beta-lactamase-producing Gram-negative bacteria-an Indian experience., J. Med. Microbiol., 59, 955, 10.1099/jmm.0.018085-0 · DOI
  9. Bahar, 2004, Detection of VIM-5 metallo-beta-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey., J. Antimicrob. Chemother., 54, 282, 10.1093/jac/dkh321 · DOI
  10. Bebrone, 2013, GES-18, a new carbapenem-hydrolyzing GES-type beta-lactamase from Pseudomonas aeruginosa that contains Ile80 and Ser170 residues., Antimicrob. Agents Chemother., 57, 396, 10.1128/aac.01784-12 · DOI
  11. Bonnin, 2018, Molecular characterization of OXA-198 carbapenemase-producing Pseudomonas aeruginosa clinical isolates., Antimicrob. Agents Chemother., 62, 10.1128/AAC.02496-17 · DOI
  12. Bontron, 2016, Transposition of Tn125 encoding the NDM-1 carbapenemase in Acinetobacter baumannii., Antimicrob. Agents Chemother., 60, 7245, 10.1128/AAC.01755-16 · DOI
  13. Borah, 2016, First report on the detection of OXA-48 beta-lactamase gene in Escherichia coli and Pseudomonas aeruginosa co-infection isolated from a patient in a tertiary care hospital in Assam., Indian J. Med. Microbiol., 34, 252, 10.4103/0255-0857.176842 · DOI
  14. Bosnjak, 2010, VIM-2 beta-lactamase in Pseudomonas aeruginosa isolates from Zagreb, Croatia., Scand. J. Infect. Dis., 42, 193, 10.3109/00365540903426582 · DOI
  15. Botelho, 2018, Two decades of blaVIM-2-producing Pseudomonas aeruginosa dissemination: an interplay between mobile genetic elements and successful clones., J. Antimicrob. Chemother., 73, 873, 10.1093/jac/dkx517 · DOI
  16. Boyd, 2019, Identification of a novel metallo-beta-lactamase, CAM-1, in clinical Pseudomonas aeruginosa isolates from Canada., J. Antimicrob. Chemother., 74, 1563, 10.1093/jac/dkz066 · DOI
  17. Bryant, 2013, KPC-4 is encoded within a truncated Tn4401 in an IncL/M plasmid, pNE1280, isolated from Enterobacter cloacae and Serratia marcescens., Antimicrob. Agents Chemother., 57, 37, 10.1128/aac.01062-12 · DOI
  18. Cai, 2016, Study on the resistance mechanism via outer membrane protein OprD2 and metal beta-lactamase expression in the cell wall of Pseudomonas aeruginosa., Exp. Ther. Med., 12, 2869, 10.3892/etm.2016.3690 · DOI
  19. Cambray, 2010, Integrons., Annu. Rev. Genet., 44, 141, 10.1146/annurev-genet-102209-163504 · DOI
  20. Carattoli, 2013, Isolation of NDM-1-producing Pseudomonas aeruginosa sequence type ST235 from a stem cell transplant patient in Italy, May 2013., Euro Surveill., 18, 10.2807/1560-7917.ES2013.18.46.20633 · DOI
  21. Castanheira, 2009, Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18)., Antimicrob. Agents Chemother., 53, 1225, 10.1128/aac.01011-08 · DOI
  22. Castanheira, Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel beta-lactamases, GES-22 and VIM-35., Antimicrob. Agents Chemother., 58, 7358, 10.1128/aac.03930-14 · DOI
  23. Castanheira, Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries., J. Antimicrob. Chemother., 69, 1804, 10.1093/jac/dku048 · DOI
  24. Castanheira, 2004, Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase., Antimicrob. Agents Chemother., 48, 4654, 10.1128/aac.48.12.4654-4661.2004 · DOI
  25. Chalhoub, 2016, High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations., Int. J. Antimicrob. Agents, 48, 740, 10.1016/j.ijantimicag.2016.09.012 · DOI
  26. Chaves, 2017, High mortality of bloodstream infection outbreak caused by carbapenem-resistant P. aeruginosa producing SPM-1 in a bone marrow transplant unit., J. Med. Microbiol., 66, 1722, 10.1099/jmm.0.000631 · DOI
  27. Chen, 2014, Dissemination of IMP-6-producing Pseudomonas aeruginosa ST244 in multiple cities in China., Eur. J. Clin. Microbiol. Infect. Dis., 33, 1181, 10.1007/s10096-014-2063-5 · DOI
  28. Cheruvanky, 2017, Enhanced Klebsiella pneumoniae carbapenemase expression from a novel Tn4401 deletion., Antimicrob. Agents Chemother., 61, 10.1128/AAC.00025-17 · DOI
  29. Collis, 1993, Site-specific insertion of gene cassettes into integrons., Mol. Microbiol., 9, 41, 10.1111/j.1365-2958.1993.tb01667.x · DOI
  30. Collis, 1992, Gene cassettes from the insert region of integrons are excised as covalently closed circles., Mol. Microbiol., 6, 2875, 10.1111/j.1365-2958.1992.tb01467.x · DOI
  31. Correa, 2015, Dissemination of high-risk clones of extensively drug-resistant Pseudomonas aeruginosa in colombia., Antimicrob. Agents Chemother., 59, 2421, 10.1128/aac.03926-14 · DOI
  32. Coyne, 2010, Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray., Antimicrob. Agents Chemother., 54, 333, 10.1128/aac.01037-09 · DOI
  33. Crespo, 2004, Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia., J. Clin. Microbiol., 42, 5094, 10.1128/jcm.42.11.5094-5101.2004 · DOI
  34. Cuzon, 2011, Functional characterization of Tn4401, a Tn3-based transposon involved in blaKPC gene mobilization., Antimicrob. Agents Chemother., 55, 5370, 10.1128/aac.05202-11 · DOI
  35. Dai, 2016, The IncP-6 plasmid p10265-KPC from Pseudomonas aeruginosa carries a novel deltaISEc33-associated blaKPC-2 gene cluster., Front. Microbiol., 7, 10.3389/fmicb.2016.00310 · DOI
  36. de Oliveira Santos, 2019, Epidemiology and antibiotic resistance trends in clinical isolates of Pseudomonas aeruginosa from Rio de janeiro - Brazil: Importance of mutational mechanisms over the years (1995-2015)., Infect. Genet. Evol., 73, 411, 10.1016/j.meegid.2019.05.015 · DOI
  37. Del Barrio-Tofino, 2020, Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired beta-lactamases: 2020 update., Int. J. Antimicrob. Agents, 56, 10.1016/j.ijantimicag.2020.106196 · DOI
  38. del Pilar Garcillan-Barcia, 2001, Single-stranded DNA intermediates in IS91 rolling-circle transposition., Mol. Microbiol., 39, 494, 10.1046/j.1365-2958.2001.02261.x · DOI
  39. Delgado-Valverde, 2020, Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia., J. Antimicrob. Chemother., 75, 1840, 10.1093/jac/dkaa117 · DOI
  40. Deplano, 2007, Emergence and dissemination of multidrug resistant clones of Pseudomonas aeruginosa producing VIM-2 metallo-beta-lactamase in Belgium., Euro Surveill., 12
  41. Di Pilato, 2019, Identification of a novel plasmid lineage associated with the dissemination of metallo-beta-lactamase genes among Pseudomonas., Front. Microbiol., 10, 10.3389/fmicb.2019.01504 · DOI
  42. Di Pilato, 2015, Tn6249, a new Tn6162 transposon derivative carrying a double-integron platform and involved with acquisition of the blaVIM-1 metallo-beta-lactamase gene in Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 59, 1583, 10.1128/aac.04047-14 · DOI
  43. Diaz-Aroca, 1987, Transposition of IS91 does not generate a target duplication., J. Bacteriol., 169, 442, 10.1128/jb.169.1.442-443.1987 · DOI
  44. Docquier, 2003, On functional and structural heterogeneity of VIM-type metallo-beta-lactamases., J. Antimicrob. Chemother., 51, 257, 10.1093/jac/dkg067 · DOI
  45. Dortet, 2015, Dissemination of carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa in Romania., Antimicrob. Agents Chemother., 59, 7100, 10.1128/aac.01512-15 · DOI
  46. Dortet, 2014, Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria., Biomed. Res. Int., 2014, 10.1155/2014/249856 · DOI
  47. Edelstein, 2013, Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study., Lancet Infect. Dis., 13, 867, 10.1016/s1473-3099(13)70168-3 · DOI
  48. El Solh, 2009, Update on the treatment of Pseudomonas aeruginosa pneumonia., J. Antimicrob. Chemother., 64, 229, 10.1093/jac/dkp201 · DOI
  49. Elias, 2010, Nosocomial outbreak of VIM-2 metallo-beta-lactamase-producing Pseudomonas aeruginosa associated with retrograde urography., Clin. Microbiol. Infect., 16, 1494, 10.1111/j.1469-0691.2010.03146.x · DOI
  50. Falahat, 2016, Detection of KPC carbapenemase in Pseudomonas aeruginosa isolated from clinical samples using modified hodge test and boronic acid phenotypic methods and their comparison with the polymerase chain reaction, Jundishapur., J. Microbiol., 9
  51. Fan, 2016, Diverse genetic background of multidrug-resistant Pseudomonas aeruginosa from mainland China, and emergence of an extensively drug-resistant ST292 clone in kunming., Sci. Rep., 6
  52. Farra, 2008, Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem., Int. J. Antimicrob. Agents, 31, 427, 10.1016/j.ijantimicag.2007.12.016 · DOI
  53. Feng, 2017, Epidemiology and resistance characteristics of Pseudomonas aeruginosa isolates from the respiratory department of a hospital in China., J. Glob. Antimicrob. Resist., 8, 142, 10.1016/j.jgar.2016.11.012 · DOI
  54. Findlay, 2017, OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014., J. Antimicrob. Chemother., 72, 1340, 10.1093/jac/dkx012 · DOI
  55. Fournier, 2012, Spread of the blaIMP-13 gene in French Pseudomonas aeruginosa through sequence types ST621, ST308 and ST111., Int. J. Antimicrob. Agents, 40, 571, 10.1016/j.ijantimicag.2012.08.006 · DOI
  56. Frase, 2009, Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases., J. Biol. Chem., 284, 29509, 10.1074/jbc.m109.011262 · DOI
  57. Frere, 2005, Is it necessary to change the classification of beta-lactamases?, J. Antimicrob. Chemother., 55, 1051, 10.1093/jac/dki155 · DOI
  58. Galetti, 2016, New small plasmid harboring blaKPC-2 in Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 60, 3211, 10.1128/aac.00247-16 · DOI
  59. Garcia-Castillo, 2011, Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals., J. Clin. Microbiol., 49, 2905, 10.1128/jcm.00753-11 · DOI
  60. Garza-Ramos, 2008, Metallo-beta-lactamase gene blaIMP-15 in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico., Antimicrob. Agents Chemother., 52, 2943, 10.1128/aac.00679-07 · DOI
  61. Ge, 2011, Identification of KPC-2-producing Pseudomonas aeruginosa isolates in China., J. Antimicrob. Chemother., 66, 1184, 10.1093/jac/dkr060 · DOI
  62. Giani, 2018, Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers., J. Antimicrob. Chemother., 73, 664, 10.1093/jac/dkx453 · DOI
  63. Gibb, 2002, Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new blaIMP allele, blaIMP-7., Antimicrob. Agents Chemother., 46, 255, 10.1128/aac.46.1.255-258.2002 · DOI
  64. Golemi, 2001, Critical involvement of a carbamylated lysine in catalytic function of class D beta-lactamases., Proc. Natl. Acad. Sci. U.S.A., 98, 14280, 10.1073/pnas.241442898 · DOI
  65. Grindley, 1983, Transposition of Tn3 and related transposons., Cell, 32, 3, 10.1016/0092-8674(83)90490-7 · DOI
  66. Guindon, 2003, A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood., Syst. Biol., 52, 696, 10.1080/10635150390235520 · DOI
  67. Hagemann, 2018, KPC-2 carbapenemase-producing Pseudomonas aeruginosa reaching Germany., J. Antimicrob. Chemother., 73, 1812, 10.1093/jac/dky105 · DOI
  68. Hall, 1995, Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination., Mol. Microbiol., 15, 593, 10.1111/j.1365-2958.1995.tb02368.x · DOI
  69. Han, 2010, Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa., Proc. Natl. Acad. Sci. U.S.A., 107, 22002, 10.1073/pnas.1013092107 · DOI
  70. Hanson, 2006, First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-beta-lactamase, IMP-18., Antimicrob. Agents Chemother., 50, 2272, 10.1128/aac.01440-05 · DOI
  71. Hishinuma, 2018, Spread of GES-5 carbapenemase-producing Pseudomonas aeruginosa clinical isolates in Japan due to clonal expansion of ST235., PLoS One, 13, 10.1371/journal.pone.0207134 · DOI
  72. Honda, 2019, Isolation of three distinct carbapenemase-producing Gram-negative bacteria from a Vietnamese medical tourist., J. Infect. Chemother., 25, 811, 10.1016/j.jiac.2019.03.020 · DOI
  73. Hong, 2016, Clonal Dissemination of Pseudomonas aeruginosa Sequence Type 235 isolates carrying blaIMP-6 and emergence of blaGES-24 and blaIMP-10 on novel genomic islands PAGI-15 and -16 in South Korea., Antimicrob. Agents Chemother., 60, 7216, 10.1128/AAC.01601-16 · DOI
  74. Hrabak, 2011, Regional spread of Pseudomonas aeruginosa ST357 producing IMP-7 metallo-beta-lactamase in Central Europe., J. Clin. Microbiol., 49, 474, 10.1128/jcm.00684-10 · DOI
  75. Hrabak, 2009, First identification of metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Czech Republic., Euro Surveill., 14, 10.2807/ese.14.04.19102-en · DOI
  76. Hu, 2015, Emergence of KPC-2-producing Pseudomonas aeruginosa sequence type 463 isolates in Hangzhou, China., Antimicrob. Agents Chemother., 59, 2914, 10.1128/aac.04903-14 · DOI
  77. Jabalameli, 2018, Prevalence of metallo-beta-lactamase-encoding genes among carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Iran., Rev. Soc. Bras. Med. Trop., 51, 270, 10.1590/0037-8682-0044-2018 · DOI
  78. Jacome, 2012, First report of KPC-producing Pseudomonas aeruginosa in Brazil., Antimicrob. Agents Chemother., 56, 10.1128/aac.00699-12 · DOI
  79. Janvier, 2013, Molecular characterization of blaNDM-1 in a sequence type 235 Pseudomonas aeruginosa isolate from France., Antimicrob. Agents Chemother., 57, 3408, 10.1128/aac.02334-12 · DOI
  80. Jeannot, 2013, Outbreak of metallo-beta-lactamase VIM-2-positive strains of Pseudomonas aeruginosa in the Ivory Coast., J. Antimicrob. Chemother., 68, 2952, 10.1093/jac/dkt296 · DOI
  81. Jobanputra, 1974, Trimethoprim R factors in enterobacteria from clinical specimens., J. Med. Microbiol., 7, 169, 10.1099/00222615-7-2-169 · DOI
  82. Jovcic, 2013, The clinical isolate Pseudomonas aeruginosa MMA83 carries two copies of the blaNDM-1 gene in a novel genetic context., Antimicrob. Agents Chemother., 57, 3405, 10.1128/aac.02312-12 · DOI
  83. Jovcic, 2011, Emergence of NDM-1 metallo-beta-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia., Antimicrob. Agents Chemother., 55, 3929, 10.1128/AAC.00226-11 · DOI
  84. Juan, 2008, Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain., Antimicrob. Agents Chemother., 52, 3589, 10.1128/aac.00465-08 · DOI
  85. Karlowsky, 2017, In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015., Antimicrob. Agents Chemother., 61, 10.1128/AAC.00472-17 · DOI
  86. Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of Gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes - SMART United States 2015-2017., Clin. Infect. Dis., 10.1093/cid/ciaa381 · DOI
  87. Kateete, 2016, Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago Hospital in Kampala, Uganda (2007-2009)., Springerplus, 5, 10.1186/s40064-016-2986-7 · DOI · Paper page
  88. Kazmierczak, Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam., Antimicrob. Agents Chemother., 60, 4490, 10.1128/aac.00107-16 · DOI
  89. Kazmierczak, Multiyear, multinational survey of the incidence and global distribution of metallo-beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 60, 1067, 10.1128/aac.02379-15 · DOI
  90. Khajuria, 2013, Emergence of NDM - 1 in the clinical isolates of Pseudomonas aeruginosa in India., J. Clin. Diagn. Res., 7, 1328
  91. Khosravi, 2008, Detection of metallo-beta-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients in Ahwaz, Iran., Diagn. Microbiol. Infect. Dis., 60, 125, 10.1016/j.diagmicrobio.2007.08.003 · DOI
  92. Khosravi, 2010, Metallo-beta-lactamase-producing imipenem-resistant Pseudomonas aeruginosa clinical isolates in a university teaching hospital in Malaysia: detection of IMP-7 and first identification of IMP-4, VIM-2, and VIM-11., Diagn. Microbiol. Infect. Dis., 67, 294, 10.1016/j.diagmicrobio.2010.02.010 · DOI
  93. Khuntayaporn, 2019, Dissemination of carbapenem-resistance among multidrug resistant Pseudomonas aeruginosa carrying metallo-beta-lactamase genes, including the novel blaIMP-65 gene in Thailand., Infect. Chemother., 51, 107, 10.3947/ic.2019.51.2.107 · DOI
  94. Klockgether, 2011, Pseudomonas aeruginosa genomic structure and diversity., Front. Microbiol., 2, 10.3389/fmicb.2011.00150 · DOI
  95. Klockgether, 2004, Sequence analysis of the mobile genome island pKLC102 of Pseudomonas aeruginosa C., J. Bacteriol., 186, 518, 10.1128/jb.186.2.518-534.2004 · DOI
  96. Koh, 2010, Multilocus sequence types of carbapenem-resistant Pseudomonas aeruginosa in Singapore carrying metallo-beta-lactamase genes, including the novel blaIMP-26 gene., J. Clin. Microbiol., 48, 2563, 10.1128/jcm.01905-09 · DOI
  97. Kohler, 1999, Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems., Antimicrob. Agents Chemother., 43, 424, 10.1128/aac.43.2.424 · DOI
  98. Korfhagen, 1976, Resistance plasmids of Pseudomonas aeruginosa: change from conjugative to nonconjugative in a hospital population., Antimicrob. Agents Chemother., 9, 810, 10.1128/aac.9.5.810 · DOI
  99. Kouda, 2007, First isolation of blaIMP-7 in a Pseudomonas aeruginosa in Japan., J. Infect. Chemother., 13, 276, 10.1007/s10156-007-0520-0 · DOI
  100. Kouda, 2009, Increased prevalence and clonal dissemination of multidrug-resistant Pseudomonas aeruginosa with the blaIMP-1 gene cassette in Hiroshima., J. Antimicrob. Chemother., 64, 46, 10.1093/jac/dkp142 · DOI
  101. Krizova, 2011, Diversity and evolution of AbaR genomic resistance islands in Acinetobacter baumannii strains of European clone I., Antimicrob. Agents Chemother., 55, 3201, 10.1128/aac.00221-11 · DOI
  102. Ktari, 2011, Diversity of beta-lactamases in Pseudomonas aeruginosa isolates producing metallo-beta-lactamase in two Tunisian hospitals., Microb. Drug Resist., 17, 25, 10.1089/mdr.2010.0104 · DOI
  103. Kulkova, 2015, First report of New Delhi metallo-beta-lactamase-1-producing strains in Slovakia., Microb. Drug Resist., 21, 117, 10.1089/mdr.2013.0162 · DOI
  104. Kumarasamy, 2010, Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study., Lancet Infect. Dis., 10, 597, 10.1016/s1473-3099(10)70143-2 · DOI · Paper page
  105. Kung, 2010, The accessory genome of Pseudomonas aeruginosa., Microbiol. Mol. Biol. Rev., 74, 621, 10.1128/mmbr.00027-10 · DOI
  106. Lauretti, 1999, Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate., Antimicrob. Agents Chemother., 43, 1584, 10.1128/aac.43.7.1584 · DOI
  107. Li, 1995, Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 39, 1948, 10.1128/aac.39.9.1948 · DOI
  108. Lister, 2009, Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms., Clin. Microbiol. Rev., 22, 582, 10.1128/cmr.00040-09 · DOI
  109. Livermore, 1992, Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 36, 2046, 10.1128/aac.36.9.2046 · DOI
  110. Livermore, 1987, Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa., J. Infect. Dis., 155, 775, 10.1093/infdis/155.4.775 · DOI
  111. Lob, 2020, In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015-2017., J. Med. Microbiol., 69, 207, 10.1099/jmm.0.001142 · DOI
  112. Luyt, 2014, Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia., Antimicrob. Agents Chemother., 58, 1372, 10.1128/aac.02109-13 · DOI
  113. Mac Aogain, 2016, Identification of emergent blaCMY-2-carrying Proteus mirabilis lineages by whole-genome sequencing., New Microbes New Infect., 9, 58, 10.1016/j.nmni.2015.11.012 · DOI
  114. Malkocoglu, 2017, VIM-1, VIM-2, and GES-5 Carbapenemases among Pseudomonas aeruginosa isolates at a tertiary hospital in Istanbul, Turkey., Microb. Drug Resist., 23, 328, 10.1089/mdr.2016.0012 · DOI
  115. Manenzhe, 2015, The spread of carbapenemase-producing bacteria in Africa: a systematic review., J. Antimicrob. Chemother., 70, 23, 10.1093/jac/dku356 · DOI
  116. Mano, 2015, Molecular analysis of the integrons of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan., BMC Microbiol., 15, 10.1186/s12866-015-0378-8 · DOI
  117. Margaret, 1989, Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa., J. Antimicrob. Chemother., 24, 161, 10.1093/jac/24.suppl_a.161 · DOI
  118. Martinez, 2012, Diverse mobilized class 1 integrons are common in the chromosomes of pathogenic Pseudomonas aeruginosa clinical isolates., Antimicrob. Agents Chemother., 56, 2169, 10.1128/aac.06048-11 · DOI
  119. Masuda, 2000, Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 44, 3322, 10.1128/aac.44.12.3322-3327.2000 · DOI
  120. Matagne, 1999, The beta-lactamase cycle: a tale of selective pressure and bacterial ingenuity., Nat. Prod. Rep., 16, 1, 10.1039/a705983c · DOI
  121. Mataseje, 2016, Colistin-nonsusceptible Pseudomonas aeruginosa sequence type 654 with blaNDM-1 arrives in North America., Antimicrob. Agents Chemother., 60, 1794, 10.1128/aac.02591-15 · DOI
  122. Maurya, 2014, A report on the presence of GES-5 extended spectrum beta-lactamase producing Pseudomonas aeruginosa associated with urinary tract infection from north-east India., Indian J. Med. Res., 140, 565
  123. Mazzariol, 2011, A novel VIM-type metallo-beta-lactamase (VIM-14) in a Pseudomonas aeruginosa clinical isolate from a neonatal intensive care unit., Clin. Microbiol. Infect., 17, 722, 10.1111/j.1469-0691.2010.03424.x · DOI
  124. McCarthy, 2017, Draft Genome Sequence of an IMP-7-Producing Pseudomonas aeruginosa bloodstream infection isolate from Australia., Genome Announc., 5, 10.1128/genomeA.00596-17 · DOI
  125. McCracken, 2019, Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study., J. Antimicrob. Chemother., 74, iv32, 10.1093/jac/dkz285 · DOI
  126. Mikucionyte, 2016, Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania., Eur. J. Clin. Microbiol. Infect. Dis., 35, 195, 10.1007/s10096-015-2529-0 · DOI
  127. Minakhina, 1999, Tn5053 family transposons are res site hunters sensing plasmidal res sites occupied by cognate resolvases., Mol. Microbiol., 33, 1059, 10.1046/j.1365-2958.1999.01548.x · DOI
  128. Minami, 1996, Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase., J. Antimicrob. Chemother., 37, 433, 10.1093/jac/37.3.433 · DOI
  129. Moradali, 2017, Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, Survival, and Persistence., Front. Cell Infect. Microbiol., 7, 10.3389/fcimb.2017.00039 · DOI
  130. Moran-Barrio, 2016, Crystal structure of the metallo-beta-lactamase gob in the periplasmic dizinc form reveals an unusual metal site., Antimicrob. Agents Chemother., 60, 6013, 10.1128/aac.01067-16 · DOI
  131. Mosquera-Rendon, 2016, Pangenome-wide and molecular evolution analyses of the Pseudomonas aeruginosa species., BMC Genomics, 17, 10.1186/s12864-016-2364-4 · DOI
  132. Moura, 2009, INTEGRALL: a database and search engine for integrons, integrases and gene cassettes., Bioinformatics, 25, 1096, 10.1093/bioinformatics/btp105 · DOI
  133. Moyo, 2015, Identification of VIM-2-producing Pseudomonas aeruginosa from Tanzania is associated with sequence types 244 and 640 and the location of blaVIM-2 in a TniC integron., Antimicrob. Agents Chemother., 59, 682, 10.1128/aac.01436-13 · DOI
  134. Naas, 2013, Complete sequence of two KPC-harbouring plasmids from Pseudomonas aeruginosa., J. Antimicrob. Chemother., 68, 1757, 10.1093/jac/dkt094 · DOI
  135. Naas, 2012, Role of ISKpn7 and deletions in blaKPC gene expression., Antimicrob. Agents Chemother., 56, 4753, 10.1128/AAC.00334-12 · DOI
  136. 2020, Genome.
  137. Nho, 2008, Dissemination of the blaIMP-1 and blaVIM-2 metallo-beta-lactamase genes among genetically unrelated Pseudomonas aeruginosa isolates in a South Korean hospital., Int. J. Antimicrob. Agents, 31, 586, 10.1016/j.ijantimicag.2008.02.005 · DOI
  138. Pacheco, 2019, Pseudomonas aeruginosa Coharboring blaKPC-2 and blaVIM-2 carbapenemase genes., Antibiotics (Basel), 8, 10.3390/antibiotics8030098 · DOI
  139. Papagiannitsis, 2017, Molecular characterization of carbapenemase-producing Pseudomonas aeruginosa of Czech origin and evidence for clonal spread of extensively resistant sequence type 357 expressing IMP-7 metallo-beta-lactamase., Antimicrob. Agents Chemother., 61, 10.1128/AAC.01811-17 · DOI
  140. Papp-Wallace, 2011, Carbapenems: past, present, and future., Antimicrob. Agents Chemother., 55, 4943, 10.1128/AAC.00296-11 · DOI
  141. Pasteran, 2005, Novel variant (blaVIM-11) of the metallo-beta-lactamase blaVIM family in a GES-1 extended-spectrum-beta-lactamase-producing Pseudomonas aeruginosa clinical isolate in Argentina., Antimicrob. Agents Chemother., 49, 474, 10.1128/aac.49.1.474-475.2005 · DOI
  142. Paton, 1993, ARI 1: Beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii., Int. J. Antimicrob. Agents, 2, 81, 10.1016/0924-8579(93)90045-7 · DOI
  143. Paul, 2015, Co-carriage of blaKPC-2 and blaNDM-1 in clinical isolates of Pseudomonas aeruginosa associated with hospital infections from India., PLoS One, 10, 10.1371/journal.pone.0145823 · DOI
  144. Pfennigwerth, 2017, Genetic and biochemical characterization of HMB-1, a novel subclass B1 metallo-beta-lactamase found in a Pseudomonas aeruginosa clinical isolate., J. Antimicrob. Chemother., 72, 1068
  145. Pitout, 2007, Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region: emergence of VIM-2-producing isolates., J. Clin. Microbiol., 45, 294, 10.1128/jcm.01694-06 · DOI
  146. Pitout, 2008, Metallo-beta-lactamase-producing Pseudomonas aeruginosa isolated from a large tertiary centre in Kenya., Clin. Microbiol. Infect., 14, 755, 10.1111/j.1469-0691.2008.02030.x · DOI
  147. Poirel, 2000, Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France., Antimicrob. Agents Chemother., 44, 891, 10.1128/aac.44.4.891-897.2000 · DOI
  148. Poirel, 2010, Emergence of KPC-producing Pseudomonas aeruginosa in the United States., Antimicrob. Agents Chemother., 54, 10.1128/aac.00513-10 · DOI
  149. Poirel, 2001, GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem., Antimicrob. Agents Chemother., 45, 2598, 10.1128/aac.45.9.2598-2603.2001 · DOI
  150. Pollini, 2013, FIM-1, a new acquired metallo-beta-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy., Antimicrob. Agents Chemother., 57, 410, 10.1128/aac.01953-12 · DOI
  151. Polotto, 2012, Detection of P. aeruginosa harboring blaCTX-M-2, blaGES-1 and blaGES-5, blaIMP-1 and blaSPM-1 causing infections in Brazilian tertiary-care hospital., BMC Infect. Dis., 12, 10.1186/1471-2334-12-176 · DOI
  152. Pournaras, 2002, Novel variant (blaVIM-4) of the metallo-beta-lactamase gene blaVIM-1 in a clinical strain of Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 46, 4026, 10.1128/aac.46.12.4026-4028.2002 · DOI
  153. Quale, 2006, Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates., Antimicrob. Agents Chemother., 50, 1633, 10.1128/aac.50.5.1633-1641.2006 · DOI
  154. Queenan, 2007, Carbapenemases: the versatile beta-lactamases., Clin. Microbiol. Rev., 20, 440, 10.1128/cmr.00001-07 · DOI
  155. Radstrom, 1994, Transposon Tn5090 of plasmid R751, which carries an integron, is related to Tn7, Mu, and the retroelements., J. Bacteriol., 176, 3257, 10.1128/jb.176.11.3257-3268.1994 · DOI
  156. Ramirez, 2013, Emergence of Pseudomonas aeruginosa with KPC-type carbapenemase in a teaching hospital: an 8-year study., J. Med. Microbiol., 62, 1565, 10.1099/jmm.0.059923-0 · DOI
  157. Rice, 2008, Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE., J. Infect. Dis., 197, 1079, 10.1086/533452 · DOI
  158. Rios, 2018, Extensively drug-resistant (XDR) Pseudomonas aeruginosa identified in Lima, Peru co-expressing a VIM-2 metallo-beta-lactamase, OXA-1 beta-lactamase and GES-1 extended-spectrum beta-lactamase., JMM Case Rep., 5, 10.1099/jmmcr.0.005154 · DOI
  159. Roberts, 2008, Revised nomenclature for transposable genetic elements., Plasmid, 60, 167, 10.1016/j.plasmid.2008.08.001 · DOI
  160. Robledo, 2011, Detection of the KPC gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii during a PCR-based nosocomial surveillance study in Puerto Rico., Antimicrob. Agents Chemother., 55, 2968, 10.1128/aac.01633-10 · DOI
  161. Rodriguez-Martinez, Extended-spectrum cephalosporinases in Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 53, 1766, 10.1128/aac.01410-08 · DOI
  162. Rodriguez-Martinez, Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa., Antimicrob. Agents Chemother., 53, 4783, 10.1128/aac.00574-09 · DOI
  163. Rowe-Magnus, 2002, Bacterial resistance evolution by recruitment of super-integron gene cassettes., Mol. Microbiol., 43, 1657, 10.1046/j.1365-2958.2002.02861.x · DOI
  164. Roy Chowdhury, 2016, Genomic islands 1 and 2 play key roles in the evolution of extensively drug-resistant ST235 isolates of Pseudomonas aeruginosa., Open Biol., 6, 10.1098/rsob.150175 · DOI
  165. Roy Chowdhury, 2017, Genomic islands 1 and 2 carry multiple antibiotic resistance genes in Pseudomonas aeruginosa ST235, ST253, ST111 and ST175 and are globally dispersed., J. Antimicrob. Chemother., 72, 620, 10.1093/jac/dkw471 · DOI
  166. Ryoo, 2009, Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-beta-lactamase in a Korean hospital., Diagn. Microbiol. Infect. Dis., 63, 115, 10.1016/j.diagmicrobio.2008.08.019 · DOI
  167. Salabi, 2010, First report of the metallo-beta-lactamase SPM-1 in Europe., Antimicrob. Agents Chemother., 54, 10.1128/AAC.00719-09 · DOI
  168. Samuelsen, 2010, Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion., Antimicrob. Agents Chemother., 54, 346, 10.1128/aac.00824-09 · DOI
  169. Sato, 2003, The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU., EMBO J., 22, 2959, 10.1093/emboj/cdg290 · DOI
  170. Schneider, 2008, VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany., Antimicrob. Agents Chemother., 52, 2977, 10.1128/aac.00175-08 · DOI
  171. Schweizer, 2019, Plasmid-mediated transmission of KPC-2 Carbapenemase in Enterobacteriaceae in critically ill patients., Front. Microbiol., 10, 10.3389/fmicb.2019.00276 · DOI
  172. Senda, PCR detection of metallo-beta-lactamase gene (blaIMP) in Gram-negative rods resistant to broad-spectrum beta-lactams., J. Clin. Microbiol., 34, 2909, 10.1128/jcm.34.12.2909-2913.1996 · DOI
  173. Senda, Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems., Antimicrob. Agents Chemother., 40, 349, 10.1128/aac.40.2.349 · DOI
  174. Sevillano, 2009, First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii., Pathol. Biol. (Paris), 57, 493, 10.1016/j.patbio.2008.05.002 · DOI
  175. Shapiro, 1977, Tn402: a new transposable element determining trimethoprim resistance that inserts in bacteriophage lambda., J. Bacteriol., 129, 1632, 10.1128/jb.129.3.1632-1635.1977 · DOI
  176. Shen, 2006, Extensive genomic plasticity in Pseudomonas aeruginosa revealed by identification and distribution studies of novel genes among clinical isolates., Infect. Immun., 74, 5272, 10.1128/iai.00546-06 · DOI
  177. Sherry, 2018, Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia., Int. J. Antimicrob. Agents, 52, 82, 10.1016/j.ijantimicag.2018.02.017 · DOI
  178. Shi, 2018, Coexistence of two novel resistance plasmids, blaKPC–2-carrying p14057A and tetA(A) -carrying p14057B, in Pseudomonas aeruginosa., Virulence, 9, 306, 10.1080/21505594.2017.1372082 · DOI
  179. Siarkou, 2009, Molecular epidemiology of outbreak-related Pseudomonas aeruginosa strains carrying the novel variant blaVIM-17 metallo-beta-lactamase gene., Antimicrob. Agents Chemother., 53, 1325, 10.1128/aac.01230-08 · DOI
  180. Silveira, 2014, The draft genome sequence of multidrug-resistant Pseudomonas aeruginosa strain CCBH4851, a nosocomial isolate belonging to clone SP (ST277) that is prevalent in Brazil., Mem. Inst. Oswaldo Cruz, 109, 1086, 10.1590/0074-0276140336 · DOI
  181. Slack, 1981, Antipseudomonal beta-lactams., J. Antimicrob. Chemother., 8, 165, 10.1093/jac/8.3.165 · DOI
  182. Sole, 2011, First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain., Antimicrob. Agents Chemother., 55, 4402, 10.1128/aac.00642-11 · DOI
  183. Stoesser, 2017, Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli., Sci. Rep., 7, 10.1038/s41598-017-06256-2 · DOI
  184. Sun, 2016, The first report of detecting the blaSIM-2 gene and determining the complete sequence of the SIM-encoding plasmid., Clin. Microbiol. Infect., 22, 347, 10.1016/j.cmi.2015.12.001 · DOI
  185. Tada, 2019, Molecular characterization of multidrug-resistant Pseudomonas aeruginosa isolates in hospitals in Myanmar., Antimicrob. Agents Chemother., 63, 10.1128/AAC.02397-18 · DOI
  186. Tada, 2017, Pseudomonas aeruginosa clinical isolates in nepal coproducing metallo-beta-lactamases and 16S rRNA methyltransferases., Antimicrob. Agents Chemother., 61, 10.1128/AAC.00694-17 · DOI
  187. Tai, 2015, Molecular surveillance for carbapenemase genes in carbapenem-resistant Pseudomonas aeruginosa in Australian patients with cystic fibrosis., Pathology, 47, 156, 10.1097/pat.0000000000000216 · DOI
  188. Tansirichaiya, 2019, The transposon registry., Mob. DNA, 10, 10.1186/s13100-019-0182-3 · DOI
  189. Tohya, 2019, Emergence of carbapenem-resistant Pseudomonas asiatica producing NDM-1 and VIM-2 metallo-beta-lactamases in Myanmar., Antimicrob. Agents Chemother., 63, 10.1128/AAC.00475-19 · DOI
  190. Toleman, 2006, ISCR elements: novel gene-capturing systems of the 21st century?, Microbiol. Mol. Biol. Rev., 70, 296, 10.1128/mmbr.00048-05 · DOI
  191. Toleman, 2004, blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States., Antimicrob. Agents Chemother., 48, 329, 10.1128/aac.48.1.329-332.2004 · DOI
  192. Toleman, 2002, Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme., J. Antimicrob. Chemother., 50, 673, 10.1093/jac/dkf210 · DOI
  193. Treepong, 2018, Global emergence of the widespread Pseudomonas aeruginosa ST235 clone., Clin. Microbiol. Infect., 24, 258, 10.1016/j.cmi.2017.06.018 · DOI
  194. Urbanowicz, 2019, Pseudomonas aeruginosa with NDM-1, DIM-1 and PME-1 beta-lactamases, and RmtD3 16S rRNA methylase, encoded by new genomic islands., J. Antimicrob. Chemother., 74, 3117, 10.1093/jac/dkz262 · DOI
  195. Viedma, 2009, Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain., Antimicrob. Agents Chemother., 53, 4930, 10.1128/aac.00900-09 · DOI
  196. Viedma, 2012, VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175 clone, Spain., Emerg. Infect. Dis., 18, 1235, 10.3201/eid1808.111234 · DOI
  197. Villegas, 2007, First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase., Antimicrob. Agents Chemother., 51, 1553, 10.1128/aac.01405-06 · DOI
  198. Walkty, 2019, Report of a KPC-producing Pseudomonas aeruginosa isolate in Canada., J. Antimicrob. Chemother., 74, 1748, 10.1093/jac/dkz064 · DOI
  199. Walters, 2019, Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015., Emerg. Infect. Dis., 25, 1281, 10.3201/eid2507.181200 · DOI
  200. Wang, A Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum beta-lactamase., J. Antimicrob. Chemother., 57, 1261, 10.1093/jac/dkl116 · DOI

200 of 211 shown

Cited by

Sorted by citations

Metadata

Authors
Yoon, E.-J., & Jeong, S. H.
Affiliations
Yonsei University (KR)
Corresponding author
Jeong, Seok Hoon
ORCID
Venue
Frontiers in Microbiology
Publisher
Frontiers Media SA
Published
2021-02-18
Volume
12
Pages
614058-614058
ISSN
1664-302X (ISSN-L)
DOI
10.3389/fmicb.2021.614058
PMC
PMC7930500
OpenAlex
W3132586356
Cited by
221
References
1
Citations by year
2026: 30 · 2025: 47 · 2024: 38 · 2023: 46 · 2022: 48 · 2021: 12
FWCI
2.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Funders
National Research Foundation of Korea
Topics
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Physical Sciences › Environmental Science › Pollution › Pharmaceutical and Antibiotic Environmental Impacts
  • Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
Keywords
carbapenem resistance, Pseudomonas aeruginosa, carbapenemase genes, mobile genetic elements, horizontal gene transfer, integrons, transposable elements, plasmids, integrative and conjugative elements, resistance islands, antimicrobial resistance epidemiology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review